Summary A pilot study was undertaken to determine the feasibility of infusing 131I labelled monoclonal antibodies (MoAbs) into either the cavity remaining after resection of malignant glioma or into glioma cysts. Of the seven patients recruited into the study, two had cystic lesions and five resection cavities. Six of the seven were treated after relapse from primary therapy. All 
9OYttrium which will irradiate tumour/tissue to a greater depth (6 mm) is discussed in context with the biology of glioma infiltration into normal brain parenchyma.
The systemic use of monoclonal antibodies (MoAbs) as delivery vehicles for the selective targeting of therapeutic agents to malignant disease has been disappointing. This is due, predominantly, to poor penetration and insufficient accumulation of MoAb conjugates into solid tumour deposits (Sands et al., 1988) . In general, systemic administration of radioimmunoconjugates has resulted in only approximately 0.001-0.01% of the injected material being taken up into each gram of tumour (Kemshead et al., 1984) . This is independent of either the disease targeted or the MoAb used, and is thought to be brought about by factors such as a high tumour interstitial pressure, non-specific sequestration of MoAb into the reticuloendothelial system and poor penetration of conjugates through the capillary endothelium (Jain, 1990; 1991) .
The above problems have led to the clinical use of MoAb conjugates in situations where tumour access is not a limitation. Antibody conjugates have been successfully used for the treatment of diffuse haematological disease and for instillation into body compartments containing malignant infiltrates (Epenetos et al., 1987; Lashford et al., 1988) . In this context, we have concentrated on the intrathecal administration of "'I-MoAb conjugates to patients with a variety of leptomeningeal malignancies, including medulloblastoma, carcinomatous meningitis and CNS leukaemia/lymphoma (Moseley et al., 1990; Pizer et al., 1991) . Encouraging responses to therapy have been noted. However, the use of MoAbs as delivery agents in this scenario is highly selective and does not address the question of penetration into solid tumour deposits.
One approach to overcoming this problem is to instil directly the MoAb into the tumour, but this is only likely to be of value in the absence of marked metastatic spread of disease. Under these circumstances, the MoAb is being used to hold the therapeutic agent in situ rather than delivering the cytotoxic agent selectively to malignant cells. An ideal candidate for such an approach to therapy is malignant glioma, which tends to be locally invasive rather than metastatic. Current primary treatment involves surgery and external beam irradiation, and yet the outlook remains bleak, with a median survival for patients with Grade III/IV tumours of approximately 45 weeks (range 21-61) (Steward, 1989) . At relapse, further surgical intervention is possible, but the use of additional external beam radiotherapy is excluded due to limiting radiation toxicity to normal brain. As a way of localising radiation to the tumour bed, brachytherapy has been given using either sealed radiation sources or isotope colloids (Halperin et al., 1988) .
Here, we describe the feasibility of injecting "'I-MoAb into the tumour cavity of patients who have undergone surgery for recurrent malignant glioma. In addition, as a proportion of patients will present with either primary or recurrent tumours that are essentially cystic, we have investigated the potential of administering the radiolabelled MoAb directly into a cyst cavity.
In the seven patients studied, one was given two treatments, the second after further debulking surgery. Two of the patients had cystic lesions and the others were given "'I-MoAbs into resection cavities. Toxicity data are presented along with the clearance kinetics of the isotope from the injection site. Antibody retention within the tumour is prolonged, with corresponding low blood levels. Dosimetric analysis of the data indicates that bone marrow toxicity is unlikely to be dose limiting when "'I-MoAbs are administered via this route. In addition, doses to tumour are high in comparison to those achieved in therapeutic studies using systemically administered radiolabelled antibodies.
Materials and methods
Antibody radiolabelling and quality control The MoAb, ERIC-1, of the IgG, isotype was radiolabelled with "'I using the lodogen technique to a specific activity of 185-555 MBqmg-' of protein (Fraker & Speck, 1978) .
Trichloracetic acid precipitation (10%) and the detection of aggregate formation by Fast Protein Liquid Chromatography (FPLC) using a Superose 12 column. The immunoreactive fraction of each MoAb preparation was determined using a modified LINDMO assay with an excess of human brain homogenate (Lindmo et al., 1984) . Non-specific binding to brain was determined using an isotype matched control antibody and occasionally also confirmed by blockade of "3'I-ERIC-1 binding with a gross excess of non-radiolabelled antibody. Administration of '31-MoAb to patients was undertaken within 6 h of conjugation to reduce the possibility of radiolysis. Urine volume per 24 h was recorded and 1 ml samples from each 24 h collection counted as above. The daily excretion of radioisotope was calculated and from this the amount of activity remaining in the body was determined both in real terms (effective) and in relation to the amount administered (time-corrected or biological).
Scintigraphic images of the head and whole body were taken when the residual activity was low enough for the patient to be imaged. This was variable from patient to patient. Scintigraphy was undertaken with a Siemens nuclear medicine camera using a high energy collimator with 300,000 counts accrued for each image. In addition, serial measurements of radioactivity were taken from the patient's head surface using a highly collimated external radiation probe.
Equations for tumour clearance half-times were obtained by exponential fitting of the relevant points using Cricket Values of S for a variety of different target and source organs have been calculated for both penetrating (y) and non-penetrating (1) radiation (MIRD, 1971) .
Results

Immunocytochemistry and Immunoscintigraphy
The MoAb used in these studies, ERIC-1, recognises NCAM expressed on all gliomas examined (n = > 50), as well as both normal neural and astrocytic elements within the brain (Bourne et al., 1991) . Radioimmunoscintigraphy with tracer amounts of "3'I-ERIC-1 (37 MBq) showed that the conjugate predominantly remained within the tumour cyst. This was confirmed by blood and urine analysis. The diagnostic studies broadly predicted the data obtained after administration of therapeutic amounts of '3'I-MoAb. Radioimmunoscintigraphy, 7 to 21 days after administration of the therapeutic conjugate into the tumour cyst/resection cavity, indicated that the MoAb predominantly remained where it was administered and did not diffuse widely throughout the brain (Figure 1 ). From the resolution of the scans, it is not possible to determine to what degree the isotope had diffused into the brain parenchyma adjacent to the tumour.
Toxicity
Patients entered into the study were given an escalating dose of '31I-ERIC-l ranging from 1329-2193 MBq (Table I) . However, the order of patients presented in Table I does not reflect the sequence of therapy administered due to a change of study design (see below). In each case, radioimmunoconjugate consisted of mainly non-aggregated IgG, containing less than 5% free iodine. The immunoreactive fraction ranged between 61-80% (Table I) .
Minimal toxicity was observed even following administration of 2193 MBq of radioimmunoconjugate (Table II) . Acute toxicity was manifest by a minor focal fit which occurred during administration (patient 1) and by exacerbation of pre-existing raised intracranial pressure in patient 7. In both instances, symptoms were easily controllable and they resolved rapidly. Medium term toxicity was observed in two patients (3 (first injection} and 7) and was thought to be brought about by oedema occurring in and around the tumour. This was readily reversed in patient 3 (first injection) following administration of steroids. However, in patient 7 further surgery was necessary, 3 weeks after '311-MoAb injection, to remove what appeared, upon histological examination, to be predominantly necrotic tissue. Due to the in the tumour was compared with that obtained by direct counting and a high degree of concordance was observed (Figure 2) . The elimination rate constants calculated from these clearance curves are 9.473 x 10-3h-' (probe) vs 9.828 x 10-h-' (excretion) respectively. Clearance of 131I from the tumour cavity/cyst clearly followed bi-exponential kinetics in some patients and monoexponential in others (Figure 3) . The reasons underlying this are not clear. With only two patients treated with cystic lesions, it is not possible to determine if radionuclide introduced into a cyst persists longer than when introduced into a tumour cavity. For patient 3, considerable variations in clearance rate from the cavity were noted for injections 1 and 2. Prolonged retention of antibody was noted after the second injection as compared to the first. As the patient had further surgery between the two MoAb administrations, the resection cavities must be considered as separate entities. It is probably the relative 'leakiness' of the first resection cavity that resulted in a faster clearance of '31I-MoAb from the site.
Blood clearance kinetics were obtained on all patients apart from patient 6. Peak blood levels were again variable ranging from 0.13-14.8% of the injected dose (mean 4.95, median 3.47). Peak blood level times ranged from 9.25 to 147 h (mean 63, median 51 h). Again, no correlation between blood levels, peak blood times and site of administration was possibly due to small patient numbers (Figure 4 ). Whole body doses were low, ranging from 0.08-0.31 Gy (mean 0.18) ( Table III) . In patient 6, the dose calculated was only that from the tumour as no blood data was available. In patients 1, 2, 3 and 7, over 85% of the whole body dose was due to the y radiation from the tumour site as blood activity was extremely low. In patients 5 and 4 the contribution of activity from the blood represented 25 and 50% respectively of the total whole body dose due to the high peak blood levels and consequent lower activity in the tumour. Correcting whole body dose for MBq of activity administered gave a range from 7 x I0-5-l.9 x 10-4Gy/MBq (mean 1.1 x 10-4 Gy/MBq).
The bone marrow dose (Drbm) was calculated assuming contributions from whole body (13 and y), red bone marrow (due to its high blood content) (1 and Zy) and tumour (y): Doses to bone marrow ranged from 0.07-0.51 Gy (mean 0.25). In all cases, the majority (>65%) of the dose to the marrow was as a result of blood circulating activity. As might be predicted from these calculated doses, no myelosuppression was noted in any of the individuals studied. Dose to marrow per MBq of activity injected was less variable than the overall doses, ranging from 5 x 10-5-2.6 x 10-4 Gy/ MBq (mean 1.5 x 10-4). Values Time post injection (hours) Figure 4 Determination of the levels of '3'I in the blood of patients following intratumoral/intracavity injection of '31I-ERIC-1.
1 ml blood samples were counted and the level of 31I expressed is the % of the injected activity in the blood compartment. 
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Discussion
The infusion of '3'I-MoAbs directly into either a tumour resection cavity or cystic lesion is fundamentally different to using an antibody as a targeting agent. In the former instance, the antibody is used to hold the therapeutic agent in place, rather than to deliver it to malignant cells throughout the body. Our approach can therefore be regarded as a 'liquid phase brachytherapy'. In this study, we have used a MoAb that recognises NCAM expressed on all gliomas studied (n>50) as well as both normal neural and glial cells (Bourne et al., 1991) . Binding is predominantly restricted to tumour, because access to normal brain is limited. This is clearly the case, as scintigraphy after MoAb administration shows that concentration of isotope is confined to the injection site up to 3 weeks after administration of the conjugate (Figure 1) (Moi et al., 1990) . We have refrained from the use of 90Y because of concerns regarding myelosuppression seen in other studies (Stewart et al., 1990; Vriesendorp et al., 1991 The purpose of this investigation was to undertake a pilot study on the practicability of injecting radiolabelled MoAbs into tumour cysts/cavities. Bearing in mind the aggressive
